Shin Nippon Biomedical Laboratories, Ltd.

As of March 31, 2026, Shin Nippon Biomedical Laboratories, Ltd. carries a market capitalization of 58.87B, placing it among publicly traded companies globally. Its enterprise value stands at 81.96B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shin Nippon Biomedical Laboratories, Ltd.'s next confirmed earnings release is scheduled for November 10, 2026.

As of March 31, 2026, Shin Nippon Biomedical Laboratories, Ltd. has 41.63M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Shin Nippon Biomedical Laboratories, Ltd. maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Shin Nippon Biomedical Laboratories, Ltd.'s stock has declined approximately 7.35% over the past 52 weeks. The 50-day moving average sits at 1,393.62, while the 200-day moving average is 1,412.54.

As of March 31, 2026, Shin Nippon Biomedical Laboratories, Ltd. holds 18.54B in cash and equivalents against 41.26B in total debt, resulting in a net debt position of 22.25B. Total book value stands at 43.12B, with working capital of 3.66B providing operational flexibility.

Shin Nippon Biomedical Laboratories, Ltd.'s most recent stock split took place on September 27, 2005 with a 1:2 split ratio.